Encouragingly, ongoing trials, such as EVOKE and EVOKE+, are already exploring this potential for early Alzheimer's disease
Boehringer Ingelheim International GmbH Key Target Audience Market Players Investors End-users Government Authorities Consulting And Research Firm Venture capitalists Value-Added Resellers (VARs) Recent Development In March 2023, the NHS approved Wegovy, a weight reduction injectable that mimics the hormone glucagon-like peptide-1 (GLP-1) and inhibits hunger
However, a significant portion gets broken down during digestion before it reaches the bloodstream which limits how much actually reaches your skin
Comment request
doi: 10.1186/s12933-024-02178-2, 79 MagistrettiP
No representations extend beyond controlled experimental settings, and no claims are made regarding biological outcomes, clinical relevance, or applicability outside structured investigational use